This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Nuvo Pharmaceuticals Inc.
Nuvo Pharmaceuticals Inc., also known as Miravo Healthcare, is a prominent player in the pharmaceutical industry, headquartered in Canada. Founded in 2014, the company has rapidly established itself in the development and commercialisation of innovative pain management and therapeutic solutions. With a focus on unique drug delivery systems, Nuvo's core products include the well-regarded Pennsaid® and the innovative Zilretta®, which offer patients effective relief while minimising side effects. The company operates primarily in North America, with a growing presence in international markets. Nuvo Pharmaceuticals has achieved significant milestones, including strategic partnerships and a robust pipeline of products, positioning itself as a leader in the specialty pharmaceuticals sector. Its commitment to improving patient outcomes through advanced therapies underscores its reputation as a trusted name in healthcare.
DitchCarbon Score
How does Nuvo Pharmaceuticals Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Nuvo Pharmaceuticals Inc.'s score of 34 is higher than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Nuvo Pharmaceuticals Inc., headquartered in Canada, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Apotex Inc., which may influence its climate commitments and reporting practices. As of now, Nuvo Pharmaceuticals has not established any documented reduction targets or commitments to the Science Based Targets initiative (SBTi). This lack of specific targets suggests that the company may still be in the early stages of developing a comprehensive climate strategy. Given the context of the pharmaceutical industry, which is increasingly focusing on sustainability and carbon reduction, it is essential for Nuvo Pharmaceuticals to align with industry standards and set measurable climate goals. This could include initiatives to reduce Scope 1, 2, and 3 emissions, although no specific initiatives have been reported at this time. In summary, while Nuvo Pharmaceuticals Inc. has not disclosed any emissions data or reduction targets, its affiliation with Apotex Inc. may provide a framework for future climate commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | 44,817,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 20,870,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Nuvo Pharmaceuticals Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
